Niederst, Matthew J <br/><br/>
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.  [electronic resource] 

 -  Nature communications  Mar 2015 
 - 6377 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. 
<br/><br/><label>ISSN: </label>2041-1723 
<br/><br/><label>Standard No.: </label>10.1038/ncomms7377  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Adenocarcinoma of Lung<br/>Afatinib<br/>Aniline Compounds--pharmacology<br/>Antineoplastic Agents--pharmacology<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Cell Line, Tumor<br/>Disease Progression<br/>Drug Resistance, Neoplasm--drug effects<br/>ErbB Receptors--antagonists & inhibitors<br/>Erlotinib Hydrochloride--pharmacology<br/>Gefitinib<br/>Gene Expression Regulation, Neoplastic<br/>Humans<br/>Lung--drug effects<br/>Lung Neoplasms--drug therapy<br/>Mutation<br/>Protein Kinase Inhibitors--pharmacology<br/>Proto-Oncogene Proteins c-bcl-2--genetics<br/>Quinazolines--pharmacology<br/>Recurrence<br/>Retinoblastoma Protein--deficiency<br/>Signal Transduction<br/>Small Cell Lung Carcinoma--drug therapy<br/>Sulfonamides--pharmacology<br/>bcl-X Protein--genetics